NCT00780767

Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism

Angiojet Rheolytic Thrombectomy In Case of Massive Pulmonary Embolism A Prospective Single Center Feasibility and Safety Pilot Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University Hospital, Geneva · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot study is mainly aimed to evaluate the feasibility and safety of the percutaneous Angiojet Rheolytic Thrombectomy (ART) in patients presenting a MPE. Secondarily the effectiveness of this treatment modality will also be estimated.

Detailed description

Pulmonary embolism (PE) is a major cause of mortality and morbidity in our society with more than 150.000 deaths every year in the US. Usually mortality occurs in the first hour after symptoms onset (up to 11%) and may further increase up to 17% at 3 months follow-up. In case of massive PE (MPE) mortality dramatically increases up to 30% despite important improvements recently made in precocious diagnosis and aggressive medical treatments (i.e. i.v. thrombolysis). Quite often (up to 40%) in case of PE there is at least one relative fibrinolysis contraindication, and less frequently these contraindications are absolute. In these quite rare cases, where thrombolytic therapy is absolutely contraindicated, a surgical thrombo-embolectomy is advised, however this kind of challenging surgery is not available world-wide and it still remains associated with a prohibitive high rate of mortality. A less invasive alternative remains the percutaneous thrombectomy, which may further be divided into: * Aspiration thrombectomy, * Fragmentation thrombectomy, * Rheloytic thrombectomy. The first transvenous percutaneous pulmonary embolectomy was performed more than 30 years ago; however, it is only recently that, thanks to new developed technologies, phyisicians manifest an increased interest in developing this promising less invasive procedure. The angiojet rheolytic thrombectomy (ART) catheter (Angiojet : Possis medical ; Minneapolis, MN, USA) utilizes high velocity saline jets for thrombus aspiration, maceration and evacuation through the Bernoulli principle. Nowadays this technology is successfully utilized daily in the coronary and peripheral artery fields (i.e. thrombus aspiration during coronary or arterial angioplasty). Due to its safety and efficacy, demonstrated in randomized trials including patients with coronary artery disease, several recent reports also confirmed the usefulness of this ART also in extra-coronary domain (peripheral arterial and venous diseases). Massive PE, as the thrombotic coronary artery occlusion, is a life threatening clinical manifestation, therefore several centers began to manage it associating mechanical (i.e.ART) clot removal and pharmacological (i.e. lysis). The first small, retrospective non randomized series suggest the safety and efficacy of this technology, confirming its feasibility compared with the actual proposed treatment of MPE (i.e. i.v. or in-situ pulmonary thrombolysis). The first in man utilization of the Angiojet rheolytic thrombectomy for treating acute massive PE dates 1997, however in-vitro tests also revealed that Angiojet is able to successfully remove thrombus up to 14 days old, thus enlarging its usefulness also in sub-acute cases (i.e.\>14 days old thrombus). Despite the fact that indication of an i.v. fibrinolysis is worldwide accepted in case of MPE and that established lysis protocols are nowadays available, mortality remains unacceptably high (up to 30%) and bleeding related morbidity a major concern. In fact in large PE registries, up to 20% of the patients experienced major bleedings complications, and in 3% of the cases this was intracranial. Of interest in case of sub-massive PE (sub-MPE), which is also associated with a quite high mortality (up to 8%) some disagreement concerning the best treatment modality still persists. Several authors support an intensive treatment modality favourizing the systemic i.v. thrombolysis; however, others suggest a more conservative attitude (anticoagulation alone with fibrinolysis only in case of clinical deterioration). These cases of sub-MPE may be very challenging, because an established consensus of the definition of sub-MPE combining clinical, radiological and cardiological criteria are still lacking. Furthermore the thrombolytic regimen is not complication-free, suggesting that, before performing an i.v. thrombolysis, the physician in charge of the patient has to seriously take in consideration all the absolute and the relative contra-indications of such a treatment. (i.e.recent surgery, active peptic ulcer, intra-cerebral bleeding, pregnancy, neoplasm, see Table 1). The ongoing debate on how to improve mortality in patients with MPE and concerning the correct managing of patients with sub-MPE suggests that in both cases, there is an urgent need of improving the actual treatment modalities.

Conditions

• Pulmonary Embolism

Interventions

Type	Name	Description
DEVICE	ANGIOJET RHEOLYTIC THROMBECTOMY	The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.

Timeline

• Start date: 2008-09-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2008-10-28
• Last updated: 2012-08-16

Locations

1 site across 1 country: Switzerland